Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyrvinium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.89 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.89 |
| ▸ | OPRD1 known ✓ | P41143 | 1/20 | 0.89 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.89 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.89 |
| ▸ | AR | P10275 | 2/20 | 0.89 |
| ▸ | CNR1 | P21554 | 2/20 | 0.89 |
| ▸ | SYNJ2 | O15056 | 1/20 | 0.89 |
| ▸ | MLNR | O43193 | 1/20 | 0.89 |
| ▸ | SYNJ1 | O43426 | 1/20 | 0.89 |
| ▸ | PGR | P06401 | 1/20 | 0.89 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.89 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.89 |
| ▸ | DRD2 | P14416 | 1/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.89 |
| ▸ | MAOA | P21397 | 1/20 | 0.89 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrvinium SCHEMBL19457668 | 0.94 | AR (0.89) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL149062 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL30642307 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL149063 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL29387513 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL16291465 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL30383133 | 0.94 | AR (1.00) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL646419 | 0.93 | AR (0.98) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL21111996 | 0.93 | AR (0.98) | ARCNR1SYNJ2MLNRSYNJ1 | |
| Pyrvinium SCHEMBL646420 | 0.93 | AR (0.98) | ARCNR1SYNJ2MLNRSYNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3442956-B1 | A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF | URQUIMA SA (ES) | 2024-03-27 | — | — | EP | disclosed |
| EP-3442956-A1 | A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF | URQUIMA, S.A. (ES) | 2019-02-20 | — | — | EP | disclosed |
| WO-2017178524-A1 | A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF | URQUIMA, S.A (ES) | 2017-10-19 | — | — | WO | disclosed |
| EP-3231796-A1 | A PROCESS FOR THE PREPARATION OF PYRVINIUM PAMOATE AND CRYSTALLINE FORMS THEREOF | Urquima S.A. (ES) | 2017-10-18 | — | — | EP | disclosed |
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | IMMUSOL INCORPORATED (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1841428-A1 | NOVEL QUINOLINIUM SALTS AND DERIVATIVES | Immusol Incorporated (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006078754-A1 | NOVEL QUINOLINIUM SALTS AND DERIVATIVES | IMMUSOL INCORPORATED (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080281105-A1 | Novel Quinolinium Salts and Derivatives | NQO2, MCL1, KRAS | ADRB1 2745/4885HRH1 4344/4885OPRD1 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.